Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24.

The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...